Programme
Scientific ProgrammeThursday, January 31, 2019
Opening Talk
| Time | Presentation Title | Speaker |
| 08:30 – 09:00 | Opening and Objectives | W. Oyen, G. Chételat |
Thursday, January 31, 2019
PET as Part of the Biomarker Toolbox for Early Clinical Diagnosis of Alzheimer Disease (AD)
Chairpersons: J. Arbizu / V. Garibotto / P. Scheltens / S. Minoshima
| Time | Presentation Title | Speaker |
| 09:00 – 09:20 | Unmet Need for Early Diagnosis of Prodromal AD | B. Dubois |
| 09:25 – 09:45 | Contribution of MRI for Early Diagnosis of AD | G. Frisoni |
| 09:50 – 10:10 | Contribution of CSF for Early Diagnosis of AD | H. Zetterberg |
| 10:15 – 10:35 | Contribution of PET for Early Diagnosis of AD | S. Minoshima |
| 11:00 – 11:10 | Controversy: Early Diagnosis of AD – PET in the Initial Work-Up | J. Arbizu |
| 11:10 – 11:35 | Controversy: Against | P. Scheltens |
| 11:40 – 12:05 | Controversy: In Favour | F. Nobili |
| 12:05 – 12:15 | Questions & Answers | all |
| 12:15 – 13:00 | Consensus on Imaging for Early Diagnosis of AD | S. Minoshima, J. Arbizu, V. Garibotto |
Thursday, January 31, 2019
Molecular Imaging in the Differential Diagnosis of Dementia
Chairpersons: S. Morbelli / J. Arbizu
| Time | Presentation Title | Speaker |
| 14:00 – 14:25 | Contribution of MRI | F. Agosta |
| 14:30 – 14:55 | Unmet Clinical Needs and Contribution of PET in Frontotemporal Lobar Degeneration | G. Rabinovici |
| 15:00 – 15:25 | Unmet Clinical Needs and Contribution of Molecular Imaging in Parkinsonian Syndromes | D. J. Brooks |
| 16:00 – 16:10 | Controversy: FDG-First versus Amyloid-First for Differential Dementia Diagnosis? | J. Arbizu |
| 16:15 – 16:35 | Controversy: FDG PET-First | D. Perani |
| 16:35 – 17:00 | Controversy: Amyloid PET-First | R. Ossenkoppele |
| 17:00 – 17:10 | Questions & Answers | all |
| 17:10 – 18:00 | Consensus on Molecular Imaging for Differential Dementia Diagnosis | J. Arbizu, S. Morbelli |
Friday, February 1, 2019
Clinical Acceptance of Amyloid Imaging
Chairpersons: V. Garibotto / A. Drzezga
| Time | Presentation Title | Speaker |
| Round Table: Evidence for a Routine Use of Amyloid Markers | ||
| 09:00 – 09:30 | Introduction: The Current Status of Amyloid Markers (PET and CSF) Reimbursement and the Point of View of the Payers and the Industry in the IMI-2 Initiative |
G. Frisoni |
| 09:35 – 09:50 | Clinical Use of “Freely Accessible” Amyloid Markers – The Example of Sweden | A. Nordberg |
| 09:55 – 10:15 | The Point of View of the Patients and the Families | M. C. Carrillo |
| 10:20 – 10:40 | The Point of View of the Scientific Community | S. Landau |
| 11:00 – 11:20 | Ongoing Studies to Provide Answers – AMYPAD and Other European Initiatives | F. Barkhof |
| 11:25 – 11:45 | Ongoing Studies to Provide Answers – IDEAS and Other Collaborative Efforts Worlwide | G. Rabinovici |
| Discussion and Consensus | ||
| 11:50 – 12:30 | Consensus on Clinical Use of Amyloid Markers | A. Drzezga |
| 12:30 – 13:00 | Consensus on Research Priorities | V. Garibotto |
Friday, February 1, 2019
The Use of PET in Dementia Research
Chairpersons: H. Barthel / G. Chételat / A. Drzezga
| Time | Presentation Title | Speaker |
| 14:00 – 14:20 | Impact of Brain Connectivity and Reserve in Dementia | G. Chételat |
| Round Table: The Complementarity of Neuroimaging Techniques in Clinical Trials i) to Enrich Target Populations and ii) to Monitor Drug Effects | ||
| 14:25 – 14:45 | FDG-PET Imaging | K. Herholz |
| 14:50 – 15:10 | MR Imaging | P. Scheltens |
| 15:15 – 15:35 | Amyloid and Tau-PET Imaging | V. Villemagne |
| 16:00 – 16:10 | Controversy: Guidelines for Research Criteria in Preclinical AD: Should Amyloid be Considered as the Lead Biomarker in the Hierarchy? | G. Chételat |
| 16:15 – 16:35 | Controversy: In Favour | C. Jack |
| 16:40 – 17:00 | Controversy: Against | A. Fjell |
| 17:00 – 17:35 | Consensus on Hierarchy of Biomarkers in Preclinical AD | G. Chételat |
| 17:40 – 18:00 | Do we Need Multimodal Imaging? | A. Drzezga |
Saturday, February 2, 2019
New Developments and Methodology
Chairpersons: A. Lammertsma / E. van de Giessen / H. Barthel
| Time | Presentation Title | Speaker |
| 09:00 – 09:20 | Imaging of Neuroinflammation in Neurodegeneration – What does it Add to Our Understanding? | D. J. Brooks |
| 09:25 – 09:45 | Principles of Absolute PET Quantification for Monitoring Longitudinal Treatment Response? | A. Lammertsma |
| 09:50 – 10:10 | Amyloid and Tau Imaging: Centiloid, Centaur, and Clinical Use | V. Villemagne |
| 10:15 – 10:35 | PET-Tau Imaging for Early and Differential Diagnosis of AD | O. Hansson |
| 11:00 – 11:20 | Standards for In-Vitro Validation of PET Tracers in Neurodegeneration | A. Nordberg |
| 11:25 – 11:55 | Hybrid PET/MRI: Has it Developed the Dementia Field? |
H. Barthel |
| 12:00 – 12:20 | Issues in Quantification for Neurological PET Studies | B. Hutton |
| 12:25 – 13:00 | Discussion: What else do We Need for Progress? (New Tracers, Artificial Intelligence, etc.) |
A. Lammertsma, E. van de Giessen |